Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07066189 · ClinicalTrials.gov registry record · NA

Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC

A NA study of Triple Negative Breast Cancer, sponsored by Yale University.

Recruiting
Registry status
NA
Development phase
160
Enrollment target
1
Study location

NCT07066189: Recruiting NA study of Triple Negative Breast Cancer, sponsored by Yale University.

NCT07066189 is a NA study of Triple Negative Breast Cancer that is actively recruiting participants, run by Yale University. The registered enrollment target is 160 participants, below the 245-participant average among 118 other Triple Negative Breast Cancer trials with a reported enrollment target (35% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07066189, a NA study of Triple Negative Breast Cancer, is actively recruiting participants, sponsored by Yale University.

RECRUITING
Registry status
NA
Development phase
160 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to examine whether a nutrition and exercise program can improve pathologic complete response (pCR) in women with triple-negative breast cancer (TNBC) receiving chemo-immunotherapy before surgery. Pathologic complete (pCR) response means that no cancer in the breast is seen after chemotherapy.

Primary Outcome

Pathologic Complete Response (pCR) is defined as having no invasive residual disease in the breast or regional lymph nodes after completing neoadjuvant chemotherapy (ypT0 ypN0 or ypT0/is ypN0)

Interventions

  • BEHAVIORAL Exercise and Medical Nutrition

Study Locations (1)

Connecticut

  • Yale University - New Haven

Trial Details

FieldValue
Enrollment Target 160 participants
Start Date 2025-10-17
Est. Completion 2029-10
Phase NA
Yale University

1,492 total trials

What NCT07066189 shows while recruiting

NCT07066189 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 245-participant average among 118 other Triple Negative Breast Cancer trials with a reported enrollment target (35% lower).

The record links to 1 condition, with Triple Negative Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Exercise and Medical Nutrition is the first listed.

NCT07066189 reports a single indexed study location in Connecticut.

Frequently Asked Questions

What is clinical trial NCT07066189 about?

NCT07066189 is a clinical study titled "Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC". The purpose of this study is to examine whether a nutrition and exercise program can improve pathologic complete response (pCR) in women with triple-negative breast cancer (TNBC) receiving chemo-immunotherapy before surgery. Pathologic complete (pCR) response means that no cancer in the breast is se...

What is the current status of trial NCT07066189?

This trial is currently recruiting. It is a NA study. The enrollment target is 160 participants. The study started on 2025-10-17. Estimated completion is 2029-10.

What conditions does trial NCT07066189 study?

This clinical trial studies the following conditions: Triple Negative Breast Cancer.

What interventions are being tested in trial NCT07066189?

The interventions under investigation include: Exercise and Medical Nutrition (BEHAVIORAL).

Who is sponsoring clinical trial NCT07066189?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07066189 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Triple Negative Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07066189's enrollment target sits among peer trials

160 39th of 118 higher than 80 of 118 other Triple Negative Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Triple Negative Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00501826 · 160 participants · Phase 2

    Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

  • NCT00932139 · 160 participants · NA

    Effect of Electro-Acupuncture on Blood Pressure

  • NCT00992901 · 160 participants · Early Phase 1

    Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery

  • NCT01515527 · 160 participants · Phase 2

    Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07066189, the US trial registry maintained by the National Library of Medicine. NCT07066189 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.